We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
FDA Places Clinical Hold on Gilead's HIV Studies, Stock Down
Read MoreHide Full Article
Key Takeaways
GILD's HIV studies on GS-1720 and GS-4182 were paused due to CD4 and lymphocyte count concerns.
The clinical hold affects two phase II/III trials and three phase I studies of GILD's HIV candidates.
Biktarvy and Descovy remain strong performers as GILD pushes forward with lenacapavir for HIV prevention.
Gilead Sciences, Inc. (GILD - Free Report) announced that the FDA has placed a clinical hold on studies on pipeline candidates, GS-1720 and/or GS-4182, for the treatment of HIV.
GS-1720 is an investigational integrase strand transfer inhibitor and/or GS-4182 is an investigational capsid inhibitor.
Shares were down 2.6% on the news.
Year to date, shares of GILD have gained 20% against the industry’s decline of 0.5%.
Image Source: Zacks Investment Research
More on GILD’s HIV Treatments
The FDA placed a clinical hold on the studies due to the identification of a safety signal of decreases in CD4+T-cell (CD4) and absolute lymphocyte counts in a subset of participants receiving the combination of GS-1720 and GS-4182.
The studies that have been placed on hold are a phase II/III study evaluating the safety and efficacy of oral weekly regimen of GS-1720 in combination with GS-4182 versus Biktarvy in virologically suppressed people with HIV-1 and a phase II/III study evaluating the safety and efficacy of oral weekly regimen of GS-1720 in combination with GS-4182 versus Biktarvy in treatment-naive people with HIV-1.
Three additional phase I studies of either these candidates/or their combinations are also on hold.
While the clinical hold will somewhat derail the development program for these candidates, GILD is a market leader in HIV treatments.
GILD’s Leading HIV Franchise Will Continue Momentum
Gilead’s flagship drug, Biktarvy (bictegravir 50 mg/emtricitabine 200 mg/tenofovir alafenamide 25 mg, BIC/FTC/TAF), for HIV-1 infection has become the leading prescribed regimen for both treatment-naïve and switch patients. Biktarvy accounts for over 51% share of the treatment market in the United States and should maintain momentum for GILD in the upcoming quarters.
Descovy (FTC 200 mg/TAF 25 mg) for pre-exposure prophylaxis (PrEP) is also witnessing good uptake. It maintains over 40% market share in the PrEP market in the United States.
Gilead’s efforts to innovate its HIV portfolio are impressive. Late-stage studies, PURPOSE 1 and PURPOSE 2, validated lenacapavir’s potential to prevent HIV. The FDA accepted new drug application submissions for twice-yearly lenacapavir for HIV prevention under priority review, with a target action date of June 19, 2025.
Gilead Sciences, Inc. Price, Consensus and EPS Surprise
The European Medicines Agency validated the Marketing Authorization Application and EU-Medicines for All application for twice-yearly lenacapavir for HIV prevention.
The successful development and potential approval of lenacapavir for the prevention of the disease should solidify Gilead’s HIV franchise.
Per GILD, lenacapavir, with its twice-yearly dosing, could set a new bar for HIV prevention and allow PrEP to reach out to a larger number of people who could benefit from a prevention regimen.
However, Biktarvy sales are expected to be under pressure due to Medicare Part D redesign, which, in turn, should affect overall HIV growth.
Gilead’s faces stiff competition from GSK plc (GSK - Free Report) in the HIV space.
GSK’s HIV portfolio sales are being driven by strong patient demand for Cabenuva, Apretude and Dovato. The company is also focused on the development of the next generation of HIV innovation with integrase inhibitors (INSTIs) for HIV treatment and prevention.
The Zacks Consensus Estimate Novartis’ 2025 earnings per share (EPS) has risen from $8.46 to $8.74 over the past 60 days. EPS estimates for 2026 have jumped 35 cents to $9.02 during this timeframe. The stock has risen 24.7% so far this year.
BAYRY’s 2025 EPS estimate has increased from $1.19 to $1.25 for 2025 over the past 60 days, while that for 2026 has gone up from $1.28 to $1.31 over the same timeframe. Year to date, shares of Bayer have surged 56.7%.
BAYRY’s earnings beat estimates in one of the trailing four quarters, matched twice and missed on the remaining occasion, the average negative surprise being 13.91%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Shutterstock
FDA Places Clinical Hold on Gilead's HIV Studies, Stock Down
Key Takeaways
Gilead Sciences, Inc. (GILD - Free Report) announced that the FDA has placed a clinical hold on studies on pipeline candidates, GS-1720 and/or GS-4182, for the treatment of HIV.
GS-1720 is an investigational integrase strand transfer inhibitor and/or GS-4182 is an investigational capsid inhibitor.
Shares were down 2.6% on the news.
Year to date, shares of GILD have gained 20% against the industry’s decline of 0.5%.
Image Source: Zacks Investment Research
More on GILD’s HIV Treatments
The FDA placed a clinical hold on the studies due to the identification of a safety signal of decreases in CD4+T-cell (CD4) and absolute lymphocyte counts in a subset of participants receiving the combination of GS-1720 and GS-4182.
The studies that have been placed on hold are a phase II/III study evaluating the safety and efficacy of oral weekly regimen of GS-1720 in combination with GS-4182 versus Biktarvy in virologically suppressed people with HIV-1 and a phase II/III study evaluating the safety and efficacy of oral weekly regimen of GS-1720 in combination with GS-4182 versus Biktarvy in treatment-naive people with HIV-1.
Three additional phase I studies of either these candidates/or their combinations are also on hold.
While the clinical hold will somewhat derail the development program for these candidates, GILD is a market leader in HIV treatments.
GILD’s Leading HIV Franchise Will Continue Momentum
Gilead’s flagship drug, Biktarvy (bictegravir 50 mg/emtricitabine 200 mg/tenofovir alafenamide 25 mg, BIC/FTC/TAF), for HIV-1 infection has become the leading prescribed regimen for both treatment-naïve and switch patients. Biktarvy accounts for over 51% share of the treatment market in the United States and should maintain momentum for GILD in the upcoming quarters.
Descovy (FTC 200 mg/TAF 25 mg) for pre-exposure prophylaxis (PrEP) is also witnessing good uptake. It maintains over 40% market share in the PrEP market in the United States.
Gilead’s efforts to innovate its HIV portfolio are impressive. Late-stage studies, PURPOSE 1 and PURPOSE 2, validated lenacapavir’s potential to prevent HIV. The FDA accepted new drug application submissions for twice-yearly lenacapavir for HIV prevention under priority review, with a target action date of June 19, 2025.
Gilead Sciences, Inc. Price, Consensus and EPS Surprise
Gilead Sciences, Inc. price-consensus-eps-surprise-chart | Gilead Sciences, Inc. Quote
The European Medicines Agency validated the Marketing Authorization Application and EU-Medicines for All application for twice-yearly lenacapavir for HIV prevention.
The successful development and potential approval of lenacapavir for the prevention of the disease should solidify Gilead’s HIV franchise.
Per GILD, lenacapavir, with its twice-yearly dosing, could set a new bar for HIV prevention and allow PrEP to reach out to a larger number of people who could benefit from a prevention regimen.
However, Biktarvy sales are expected to be under pressure due to Medicare Part D redesign, which, in turn, should affect overall HIV growth.
Gilead’s faces stiff competition from GSK plc (GSK - Free Report) in the HIV space.
GSK’s HIV portfolio sales are being driven by strong patient demand for Cabenuva, Apretude and Dovato. The company is also focused on the development of the next generation of HIV innovation with integrase inhibitors (INSTIs) for HIV treatment and prevention.
GILD’s Zacks Rank and Stocks to Consider
Gilead currently carries a Zacks Rank #3 (Hold). A couple of better-ranked stocks in the pharma/biotech sector are Novartis (NVS - Free Report) and Bayer (BAYRY - Free Report) , both carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
The Zacks Consensus Estimate Novartis’ 2025 earnings per share (EPS) has risen from $8.46 to $8.74 over the past 60 days. EPS estimates for 2026 have jumped 35 cents to $9.02 during this timeframe. The stock has risen 24.7% so far this year.
BAYRY’s 2025 EPS estimate has increased from $1.19 to $1.25 for 2025 over the past 60 days, while that for 2026 has gone up from $1.28 to $1.31 over the same timeframe. Year to date, shares of Bayer have surged 56.7%.
BAYRY’s earnings beat estimates in one of the trailing four quarters, matched twice and missed on the remaining occasion, the average negative surprise being 13.91%.